Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OraSure

This article was originally published in The Gray Sheet

Executive Summary

Third-quarter substance abuse test sales were up 31% to approximately $3.6 mil. compared with the year-ago period, the firm reports. During a Nov. 9 earnings call, CEO Douglas Michels cited three cases in which results from OraSure's Intercept oral fluid drug test were accepted as evidence by a court. "The legal defensibility of our test is very important to our customers, and these cases represent yet additional confirmation of the reliability and accuracy" of the oral fluid test, Michels explained...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT022903

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel